Vaxart (NASDAQ:VXRT) Stock Crosses Below Two Hundred Day Moving Average - Here's What Happened

Vaxart, Inc. (NASDAQ:VXRT - Get Free Report) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.56 and traded as low as $0.46. Vaxart shares last traded at $0.46, with a volume of 1,225,503 shares trading hands.

Analyst Ratings Changes

VXRT has been the subject of a number of research reports. Wall Street Zen upgraded Vaxart to a "hold" rating in a research note on Thursday, May 22nd. B. Riley reduced their price objective on Vaxart from $2.50 to $2.00 and set a "buy" rating for the company in a research note on Thursday, March 27th.

Vaxart Price Performance

The company has a market cap of $99.69 million, a PE ratio of -1.07 and a beta of 1.27. The stock has a 50 day simple moving average of $0.40 and a two-hundred day simple moving average of $0.56.

Vaxart (NASDAQ:VXRT - Get Free Report) last released its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.07). The business had revenue of $20.88 million for the quarter, compared to analyst estimates of $2.85 million. Vaxart had a negative return on equity of 110.46% and a negative net margin of 431.61%. As a group, equities analysts anticipate that Vaxart, Inc. will post -0.39 EPS for the current fiscal year.

Insider Activity

In related news, insider Steven Lo bought 100,000 shares of the company's stock in a transaction dated Monday, May 19th. The shares were acquired at an average price of $0.49 per share, with a total value of $49,000.00. Following the completion of the acquisition, the insider now owns 100,000 shares in the company, valued at approximately $49,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 2.90% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of VXRT. Goldman Sachs Group Inc. acquired a new position in Vaxart during the first quarter worth $31,000. Graham Capital Management L.P. grew its holdings in Vaxart by 155.8% during the fourth quarter. Graham Capital Management L.P. now owns 53,331 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 32,482 shares during the period. Sequoia Financial Advisors LLC grew its holdings in Vaxart by 140.9% during the fourth quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 35,213 shares during the period. Invesco Ltd. grew its holdings in Vaxart by 48.6% during the fourth quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company's stock worth $50,000 after acquiring an additional 24,803 shares during the period. Finally, Virtu Financial LLC acquired a new position in Vaxart during the first quarter worth $56,000. Institutional investors and hedge funds own 18.05% of the company's stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.